Renal biopsy findings in new-onset XXXX with @entity8 .

@entity1 @entity644 @entity8 @entity1252 @entity1988 @entity810 @entity1985 @entity811
OBJECTIVES: Renal biopsy has been used extensively in @entity1252 ( @entity1252 ) with @entity8 . However, there is no complete agreement about the need for renal biopsy at presentation. The goal of this study is to define the role of renal biopsy as a therapeutic guide in new-onset @entity1252 with @entity8 . METHODS: We retrospectively analyzed renal biopsy findings in 131 @entity1252 @entity1 who received renal biopsy within 3 months from the diagnosis of @entity1252 . RESULTS: In @entity1 presenting with @entity810 , 91% of @entity1 had proliferative @entity1988 ( @entity1988 ) (class IV, mixed class V + III) and 9% had non-proliferative @entity8 (pure class V). In @entity1 presenting with @entity1985 range @entity644 , proliferative @entity1988 (class III, IV, mixed class V + III) and non-proliferative @entity8 (class II, pure class V) accounted for 55% and 36% of @entity1 , respectively, whereas 9% had @entity8 . With the exception of anti-double-stranded DNA, no clinical findings correlated with pathology. In @entity1 presenting with sub- @entity1985 @entity644 , 49% of @entity1 had proliferative @entity1988 (class III, IV, mixed class V + III) and 51% had non-proliferative @entity8 (class II, pure class V). Decreased C4 levels were more common in @entity1 with proliferative @entity1988 (P = 0.031). In @entity1 presenting with @entity811 , all were not active form @entity8 . CONCLUSIONS: Our data suggested that similar clinical features may be observed despite very different classes of @entity1988 . Therefore, in new-onset @entity1252 @entity1 with @entity8 , early renal biopsy may be helpful in planning the treatment.
